Fertility Research and Practice

Table 2 Cancer diagnoses of women undergoing fertility preservation

From: Responses to fertility treatment among patients with cancer: a retrospective cohort study

Pre-therapy diagnosis	n (%)
Breast	79 (53.7)
Breast cancer type^a
Estrogen Receptor Positive	64 (81.0)
Estrogen Receptor Negative	15 (19.0)
Inflammatory	2 (2.5)
HER-2 Positive	18 (22.8)
BRCA status^b
Negative	51 (64.6)
BRCA-1 Positive	7 (8.9)
BRCA-2 Positive	6 (7.6)
BRCA-1 and − 2 Positive	0 (0.0)
Gynecologic	8 (5.4)
Ovarian	1 (0.7)
Endometrial	4 (2.7)
Cervical	5 (3.4)
Hematologic	38 (25.9)
Leukemia	11 (7.5)
Hodgkin’s lymphoma	18 (12.2)
Non-Hodgkin’s lymphoma	1 (0.7)
Myelodysplasia	2 (1.4)
Gastrointestinal	6 (4.1)
Brain	6 (4.1)
Other	11 (7.5)
Total	147^c (100)

^a Breast cancer type percentages reported as percent of all breast cancers
^b BRCA status percentages reported as percent of all breast cancers. Fifteen patients had an unknown BRCA mutation carrier status
^c One patient was diagnosed with both primary breast and thyroid (other) malignancy at the same time, and is thus only represented once in the Total row

Back to article page

ISSN: 2054-7099

Contact us

Submission enquiries: lyndie.manicani@springernature.com
General enquiries: info@biomedcentral.com